Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
General and Administrative Expenses: $6.3 million for Q4 2024, $26.7 million for the full year 2024. Net Loss: $13.9 million or $0.05 per share for Q4 2024, $54.1 million or $0.20 per share for the full year 2024. Cash and Restricted Cash: $58.8 million as of December 31, 2024. Warning! GuruFocus has detected 3 Warning Signs with OCGN. Release Date: March 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Ocugen Inc ( NASDAQ:OCGN ) has reached an alignment with the FDA to move forward with a Phase 2/3 pivotal confirmatory trial for OCU410ST, potentially expediting the clinical development timeline by two to three years. The company secured $65 million in equity and debt financings in the second half of 2024, extending its cash runway into the first quarter of 2026. OCU400, Ocugen's lead candidate, received a positive opinion from the European Medicines Agency for advanced therapy medicinal pro
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit [Yahoo! Finance]Yahoo! Finance
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease SummitGlobeNewswire
- How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments [Yahoo! Finance]Yahoo! Finance
- Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference [Yahoo! Finance]Yahoo! Finance
- Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity ConferenceGlobeNewswire
OCGN
Earnings
- 8/1/25 - In-Line
OCGN
Sec Filings
- 12/8/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- OCGN's page on the SEC website